2024-09-20
On September 11, 2024, the Hong Kong International Biotechnology Convention (BIOHK2024) was grandly opened. Frank Yang, Founding Partner & CEO of BOCG, was honored to join distinguished experts from the fields of investment, entrepreneurship, and medicine for a panel discussion on the theme, “Can Biotech Be Hong Kong’s Next Pillar of Growth?”
The third edition of BIOHK, running from September 11 to 14 at the Hong Kong Convention and Exhibition Centre, is hosted by the Hong Kong Biotechnology Organization. This year’s event, themed “Empowering Biotechnology, Advancing the Industry,” brought together high-profile figures such as Chun-ying LEUNG, Vice Chairman of the Chinese People’s Political Consultative Conference (CPPCC), Dong SUN, Secretary for Innovation, Technology and Industry of Hong Kong, Professor Albert Cheung-Hoi YU, Chairman of the Hong Kong Biotechnology Organization and BIOHK2024, and Professor Yuk-Lam LO, Honorary Chairman of the Hong Kong Biotechnology Organization. Senior executives from leading global companies were also present to witness the convention’s opening.
During his keynote speech, Chun-ying Leung emphasized the importance of Hong Kong’s closer integration with cities in the Greater Bay Area and expanding deeper cooperation beyond the region.
The panel discussion, co-hosted by Dr. Charles Hu and Josephine Wu, took place on September 11. Frank Yang, alongside Adrian Cheong and Michael Lin, shared his insights on Hong Kong’s biopharmaceutical industry and discussed strategies to drive biotech growth in the Greater Bay Area amidst the challenges posed by current geopolitical dynamics.
Frank Yang emphasized that Hong Kong is making significant strides in technological innovation, driven by enhanced biotech infrastructure and supportive policy frameworks. He noted that the establishment of the Centre for Medical Products Regulation (CMPR) is a pivotal step in cementing Hong Kong’s role as a global hub for medical innovation. It not only helps Chinese biotech companies expand internationally but also facilitates the entry of overseas companies into the Chinese market.
Frank Yang also stressed the need for Hong Kong to further harness global innovation resources, attract top industry talent, and develop more efficient mechanisms for translating innovations into commercial successes. The discussion also covered topics such as valuation trends in Hong Kong’s capital markets and strategies for corporate financing to ensure the continued growth of the biotechnology sector in the Greater Bay Area, despite external challenges.
Looking ahead, BOCG is committed to supporting the biotech industry’s development in the Greater Bay Area. Leveraging its international investment platform and biotech-focused ecosystem, BOCG will continue to fuel innovation and foster the integration of research, industry, and pharmaceuticals, driving growth and attracting global talent to the region.
